GURUFOCUS.COM » STOCK LIST » USA » NAS » eFFECTOR Therapeutics Inc (NAS:EFTR) » Definitions » Selling, General, & Admin. Expense
Switch to:

eFFECTOR Therapeutics (NAS:EFTR) Selling, General, & Admin. Expense

: $12.64 Mil (TTM As of Dec. 2022)
View and export this data going back to 2021. Start your Free Trial

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. eFFECTOR Therapeutics's selling, general, & admin. expense for the three months ended in Dec. 2022 was $2.75 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2022 was $12.64 Mil.


eFFECTOR Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for eFFECTOR Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22
Selling, General, & Admin. Expense
4.35 13.37 12.64

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Selling, General, & Admin. Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.32 3.44 2.97 3.49 2.75

Competitive Comparison

For the Biotechnology subindustry, eFFECTOR Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

eFFECTOR Therapeutics Selling, General, & Admin. Expense Distribution

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Selling, General, & Admin. Expense falls in comparison to its industry or sector. The grey bar indicates the Selling, General, & Admin. Expense's extreme value range as defined by GuruFocus.



eFFECTOR Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


eFFECTOR Therapeutics  (NAS:EFTR) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


eFFECTOR Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


eFFECTOR Therapeutics (NAS:EFTR) Business Description

eFFECTOR Therapeutics logo
Industry
Traded in Other Exchanges
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). Its product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT, and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes.
Executives
Mayank Gandhi officer: Chief Business Officer 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner officer: Chief Medical Officer C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc 10 percent owner 1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc 10 percent owner C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Kristen Harrington-smith director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Jonathan D Root director, 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Gallagher Brian M. Jr. director, 10 percent owner C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN

eFFECTOR Therapeutics (NAS:EFTR) Headlines

Other Sources